mesowatch
mesowatch
Katie Duquette

Reading Time: 13 mins

Last Modified: November 24, 2022

Page Features:4 cited research

Katie Duquette - editor

Katie Duquette, Esquire, edits our legal and medical content. She works as a clinical research coordinator in neurology at Thomas Jefferson University and received her law degree in 2016 from Villanova University School of Law. She is a licensed attorney in the District of Columbia. 

Jump to a topic


Related Pages

divider

warning icon

Find out if you qualify for a mesothelioma lawsuit.

Asbestos

Asbestos

Katie Duquette

Reading Time: 13 mins

Last Modified: November 24, 2022

Page Features:4 cited research

Katie Duquette - editor

Katie Duquette, Esquire, edits our legal and medical content. She works as a clinical research coordinator in neurology at Thomas Jefferson University and received her law degree in 2016 from Villanova University School of Law. She is a licensed attorney in the District of Columbia. 

Jump to a topic


warning icon

Find out if you qualify for a mesothelioma lawsuit.

4 References

divider

VIEW 0 MORE REFERENCES

Related Content

divider
Johnson & Johnson’s $6.5B Settlement: Long-Term Effect on Future Claims
Johnson & Johnson’s $6.5B Settlement: Long-Term Effect on Future Claims

Melissa Bill
4 mins read - May 7, 2024

Johnson & Johnson is on the verge of settling more than 50,000 lawsuits alleging that the use of its widely-used talc baby powder led to claimants developing ovarian cancer....

Settlements

Illinois Jury Awards $45M in J&J Baby Powder Case
Illinois Jury Awards $45M in J&J Baby Powder Case

Melissa Bill
3 mins read - May 3, 2024

On Friday, an Illinois court ordered Johnson & Johnson and Kenvue to pay $45 million in a case that involved a family that alleged a link between the relative’s death after...

Settlements

Revolutionizing Mesothelioma Care: New Treatment Era with ADI-PEG20
Revolutionizing Mesothelioma Care: New Treatment Era with ADI-PEG20

Mary Pieper
3 mins read - May 2, 2024

In the ongoing battle against mesothelioma, the introduction of ADI-PEG20 (pegargiminase) marks a significant milestone. This innovative drug, hailed for its novel approach,...

Treatment

© 2024 Mesowatch. All right reserved.